A few things I would caution investors on. 1. A
Post# of 30028
(Total Views: 558)
Posted On: 07/19/2019 11:17:13 PM
A few things I would caution investors on.
1. AMBS is still an OTC company.
2. No guarantee any of the deals get finalized
3. Science is a long haul. ( EXAS in 2007 was a .25 stock. maybe 5 people I know saw true potential. The rest shorted it and railed against it every dollar up...and here it is trying to break the $120 mark...12 years later)
4. MANF will not be divided off into sub groups/sub companies. It Will be invested in and or bought out or partnered with. Showing the successful spin off partnering and uplist of one of it's assets with TODOS gives the model Gerald has been working towards life and legitimacy!
5. With TODOS under its belt, that will give a Proof of Concept model that will be "undeniable"
That along with COEPTIS will give breathing room to AMBS then add in a Reg A+ along with a possible revenue generating.Hemp business puts AMBS back in the xriver seat without suffocating debt.
Not sure where Cutanogen stands, I just hope it gets bought partnered with soon. Far too many patients have suffered because of companies hoping and waiting for AMBS to fail.
It was my goal all along to see where AMBS was going on a 3-5 year plan. Gerald has never given up and is working incredible hard / diligently to pull this whole thing off.
I personally like what's happening with the company right now.
As investors we are at a turning point, one which all of us had aimed for...my goal was to invest in a company that has as many shots on goal to help as many lives as possible.
Money will follow...
Only step 1 is near completion.
That will open the door to the next step...
We are early in the game, even if it's feels like forever.
Imagine how patients have felt.... That will give some perspective on things.
GL and Much Aloha
1. AMBS is still an OTC company.
2. No guarantee any of the deals get finalized
3. Science is a long haul. ( EXAS in 2007 was a .25 stock. maybe 5 people I know saw true potential. The rest shorted it and railed against it every dollar up...and here it is trying to break the $120 mark...12 years later)
4. MANF will not be divided off into sub groups/sub companies. It Will be invested in and or bought out or partnered with. Showing the successful spin off partnering and uplist of one of it's assets with TODOS gives the model Gerald has been working towards life and legitimacy!
5. With TODOS under its belt, that will give a Proof of Concept model that will be "undeniable"
That along with COEPTIS will give breathing room to AMBS then add in a Reg A+ along with a possible revenue generating.Hemp business puts AMBS back in the xriver seat without suffocating debt.
Not sure where Cutanogen stands, I just hope it gets bought partnered with soon. Far too many patients have suffered because of companies hoping and waiting for AMBS to fail.
It was my goal all along to see where AMBS was going on a 3-5 year plan. Gerald has never given up and is working incredible hard / diligently to pull this whole thing off.
I personally like what's happening with the company right now.
As investors we are at a turning point, one which all of us had aimed for...my goal was to invest in a company that has as many shots on goal to help as many lives as possible.
Money will follow...
Only step 1 is near completion.
That will open the door to the next step...
We are early in the game, even if it's feels like forever.
Imagine how patients have felt.... That will give some perspective on things.
GL and Much Aloha
(5)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼